[Impact of Mutation on Treatment Response and Survival of Patients with Acute Myeloid Leukemia].

Objective: To investigate the expression of mutation in acute myeloid leukemia (AML) and analyze its clinical characteristics and prognosis.

Methods: A retrospective study was conducted in 212 patients with AML who were newly diagnosed in the Second Hospital of Shanxi Medical University from January 1th 2018 to June 30th 2021, including 22 patients with mutations as mutation group and 190 patients with wild type ［66 cases of them were screened by propensity score matching (PSM), as control group］. The early efficacy and survival between the two groups were compared.

Results: The median age of patients in the mutation group was 50(17-73) years old, and the ratio of male to female was 1.2:1 The main types were AML with maturation (11 cases) and acute myelomonocytic leukemia (9 cases). Prognostic stratification was carried out according to the risk stratification system of the European leukemia network in 2017, with 16 cases (72.73%) in the middle and high-risk group. At the initial diagnosis, the median count of white blood cell (WBC) was 44.75(1.30-368.71)×10/L, among which 15 cases (68.18%) were >10×10/L, and the median count of platelet (PLT) was 24(4-55)×10/L. T618I (68.18%) was a common mutation site, which had concomitant gene mutations, in which mutation was the most common (10 cases, 45.45%), but only existed in T618I mutation. The CR/CRi rate was 68.18% and 71.21% in the mutant group and the control group ( >0.05), the median over all survival time was 15 months and 9 months ( >0.05), and the median disease-free survival time was 8 months and 4 months ( >0.05), respectively.

Conclusion: Most AML patients with mutation are middle-aged patients, the main types are AML with maturation and acute myelomonocytic leukemia, and most of them have middle and high-risk prognosis. mutation may not be an independent prognostic marker for newly diagnosed AML patients.